[go: up one dir, main page]

PE20181293A1 - Plataforma de armazon de nudo de cistina - Google Patents

Plataforma de armazon de nudo de cistina

Info

Publication number
PE20181293A1
PE20181293A1 PE2018000390A PE2018000390A PE20181293A1 PE 20181293 A1 PE20181293 A1 PE 20181293A1 PE 2018000390 A PE2018000390 A PE 2018000390A PE 2018000390 A PE2018000390 A PE 2018000390A PE 20181293 A1 PE20181293 A1 PE 20181293A1
Authority
PE
Peru
Prior art keywords
amino acid
seq
loop
natural amino
cystine knot
Prior art date
Application number
PE2018000390A
Other languages
English (en)
Inventor
Rami Hannoush
Harini Kaluarachchi
Aaron NILE
Cameron Noland
Yingnan Zhang
Lijuan Zhou
Xinxin Gao
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20181293A1 publication Critical patent/PE20181293A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se refiere a un peptido de nudo de cistina (CKP) de origen no natural que se une al factor de crecimiento endotelial vascular A (VEGF-A), donde el CKP comprende la estructura de armazon de cistina: Z1C1L1C2L2C3L3C4L4C5L5C6Z2, donde Z1 y Z2 son cualquier aminoacido; L1 es el bucle 1 y tiene una estructura seleccionada del grupo que consiste en: X1X2X3X4X5X6 (SEQ ID NO:2), X1X2X3X4X5X6X7 (SEQ ID NO:3), X1X2X3X4X5X6X7X8 (SEQ ID NO:4), X1X2X3X4X5X6X7X8X9 (SEQ ID NO:5) y X1X2X3X4X5X6X7X8X9X10 (SEQ ID NO:6), donde cada uno de X1 a X10 es cualquier aminoacido; L2 es el bucle 2 y tiene la estructura: X1X2X3X4X5 (SEQ ID NO:7), donde cada X1 a X5 es cualquier aminoacido o un aminoacido no natural; L3 es el bucle 3 y tiene la estructura X1X2X3, donde cada X1 a X3 es cualquier aminoacido o un aminoacido no natural; L4 es el bucle 4 y tiene la estructura X1, donde X1 es cualquier aminoacido o un aminoacido no natural; L5 es el bucle 5 y tiene la estructura X1X2X3X4X5 (SEQ ID NO:7), donde cada uno de X1 a X5 es cualquier aminoacido o un aminoacido no natural; donde el aminoacido no natural es L-propargilglicina-PEG6-, L-sulfotirosina, entre otros. Tambien se refiere a composiciones que comprende dicho peptido. La presente invencion es util para el tratamiento de un trastorno ocular tal como enfermedad ocular proliferativa o trastorno ocular caracterizada por angiogenesis excesiva
PE2018000390A 2015-09-15 2016-09-15 Plataforma de armazon de nudo de cistina PE20181293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562219063P 2015-09-15 2015-09-15

Publications (1)

Publication Number Publication Date
PE20181293A1 true PE20181293A1 (es) 2018-08-07

Family

ID=57068206

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000390A PE20181293A1 (es) 2015-09-15 2016-09-15 Plataforma de armazon de nudo de cistina

Country Status (22)

Country Link
US (8) US10428125B2 (es)
EP (1) EP3350215B1 (es)
JP (2) JP7166916B2 (es)
KR (1) KR102846388B1 (es)
CN (4) CN108026162B (es)
AR (1) AR106032A1 (es)
AU (2) AU2016323445B2 (es)
BR (1) BR112018002263A2 (es)
CA (1) CA2996006A1 (es)
CL (2) CL2018000668A1 (es)
CO (1) CO2018002510A2 (es)
CR (1) CR20180169A (es)
IL (2) IL257399B (es)
MA (1) MA42828A (es)
MX (1) MX2018002922A (es)
MY (1) MY190552A (es)
PE (1) PE20181293A1 (es)
PH (1) PH12018500577A1 (es)
RU (1) RU2770384C2 (es)
TW (1) TWI799366B (es)
UA (1) UA125505C2 (es)
WO (1) WO2017049009A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2019233605A1 (en) * 2018-06-08 2019-12-12 BioNTech SE Compositions and methods for diagnosis and treatment of cancer
CA3183808A1 (en) 2020-06-11 2021-12-16 Genentech, Inc. Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
WO2025193946A2 (en) * 2024-03-14 2025-09-18 Genentech, Inc. Peptides binding lrrc15 and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918814A (en) 1907-10-30 1909-04-20 Handy Mfg Company Funnel.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4666884A (en) 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5747035A (en) 1995-04-14 1998-05-05 Genentech, Inc. Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997043316A1 (en) 1996-05-10 1997-11-20 Beth Israel Deaconess Medical Center, Inc. Physiologically active molecules with extended half-lives and methods of using same
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20050019826A1 (en) 2000-03-31 2005-01-27 Roselyne Tournaire Peptides blocking vascular endothelial growth factor(vegf)-mediated angiogenesis, polynucleotides encoding said pepetides and methods of use thereof
US20020106650A1 (en) 2000-06-01 2002-08-08 Paszty Christopher J. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
EP1404297B1 (en) 2001-06-12 2011-04-27 The Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
WO2003029275A2 (en) 2001-10-03 2003-04-10 Regeneron Pharmaceuticals, Inc. Anti-angiogenic peptides
GB0130738D0 (en) 2001-12-21 2002-02-06 Serono Internat S A Protein
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
NZ560504A (en) 2005-01-24 2009-07-31 Pepscan Systems Bv Binding compounds, immunogenic compounds and peptidomimetics
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
EP1926494A2 (en) 2005-06-29 2008-06-04 Carlo Pedone Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
CA2622441A1 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
TW200732347A (en) 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
WO2007131050A2 (en) 2006-05-02 2007-11-15 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2008045252A2 (en) * 2006-10-04 2008-04-17 The Board Of Trustees Of The Leland Stanford Junior University Engineered integrin binding peptides
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CA2670990A1 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
SI2274008T1 (sl) 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
WO2010048588A2 (en) * 2008-10-23 2010-04-29 Massachusetts Institute Of Technology Directed engagement of activating fc receptors
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
WO2010088548A1 (en) 2009-01-29 2010-08-05 Forsight Labs, Llc Posterior segment drug delivery
US8778888B2 (en) * 2009-11-06 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use
US20110207653A1 (en) 2009-12-21 2011-08-25 Adrian Raiche Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent
CN102740830A (zh) 2009-12-23 2012-10-17 普西维达公司 缓释递送装置
US8339139B2 (en) * 2010-01-29 2012-12-25 Infineon Technologies Ag System and method for testing a circuit
US10844106B2 (en) 2010-11-08 2020-11-24 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
EP3970723A1 (en) * 2011-02-18 2022-03-23 Asana BioSciences, LLC Aminoindane compounds for use in treating urological pain
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
JP2015528454A (ja) 2012-08-28 2015-09-28 ノバルティス アーゲー 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
GB201218278D0 (en) * 2012-10-11 2012-11-28 Cyclogenix Ltd Translocating peptide
US9587001B2 (en) * 2012-10-19 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺

Also Published As

Publication number Publication date
MX2018002922A (es) 2018-06-07
TWI799366B (zh) 2023-04-21
CL2018000668A1 (es) 2018-07-20
US20200140498A1 (en) 2020-05-07
WO2017049009A1 (en) 2017-03-23
US20240247034A1 (en) 2024-07-25
AR106032A1 (es) 2017-12-06
US11407794B2 (en) 2022-08-09
BR112018002263A2 (en) 2018-09-18
MA42828A (fr) 2018-07-25
JP7602514B2 (ja) 2024-12-18
CN114805528A (zh) 2022-07-29
IL294568A (en) 2022-09-01
CN108026162A (zh) 2018-05-11
KR102846388B1 (ko) 2025-08-18
RU2018113442A (ru) 2019-10-16
US20200115424A1 (en) 2020-04-16
UA125505C2 (uk) 2022-04-13
AU2016323445B2 (en) 2021-04-01
WO2017049009A8 (en) 2018-02-22
US20170129927A1 (en) 2017-05-11
JP7166916B2 (ja) 2022-11-08
CL2020001781A1 (es) 2020-10-23
AU2021204400B2 (en) 2023-02-02
IL257399A (en) 2018-04-30
US20200231636A1 (en) 2020-07-23
JP2022130481A (ja) 2022-09-06
CO2018002510A2 (es) 2018-05-31
RU2770384C2 (ru) 2022-04-15
IL257399B (en) 2022-08-01
EP3350215B1 (en) 2025-12-03
CN114591422B (zh) 2025-04-04
US20200325187A1 (en) 2020-10-15
PH12018500577A1 (en) 2018-10-15
MY190552A (en) 2022-04-27
JP2018533912A (ja) 2018-11-22
CN114591422A (zh) 2022-06-07
US10428125B2 (en) 2019-10-01
US20180291069A1 (en) 2018-10-11
AU2016323445A1 (en) 2018-03-01
CR20180169A (es) 2018-04-24
NZ740218A (en) 2025-05-02
US11078243B2 (en) 2021-08-03
CN108026162B (zh) 2022-04-05
CA2996006A1 (en) 2017-03-23
KR20180052718A (ko) 2018-05-18
RU2018113442A3 (es) 2020-02-17
CN120248097A (zh) 2025-07-04
HK1253318A1 (zh) 2019-06-14
US20230174596A1 (en) 2023-06-08
TW201717993A (zh) 2017-06-01
US10696721B2 (en) 2020-06-30
US11155586B2 (en) 2021-10-26
AU2021204400A1 (en) 2021-07-22
EP3350215A1 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
CL2020002796A1 (es) Derivados de gip y usos de estos
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
PE20181293A1 (es) Plataforma de armazon de nudo de cistina
PE20181517A1 (es) Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer
MX2016016868A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
PE20240015A1 (es) Proteinas de fusion gdf15 y usos de estas
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
PE20190626A1 (es) Composiciones y metodos para modular la expresion del factor b del complemento
AR081361A1 (es) Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
GT201300295A (es) "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales"
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
JO3092B1 (ar) مركب لتحفيز مسيطر عليه للمبيض
MX395266B (es) Composición farmacéutica que contiene, como ingrediente activo, proteína de fusión en la cual péptido tumor-penetrante y el agente anti-angiogénesis están fusionados, para prevenir y tratar cáncer o enfermedades relacionadas con la angiogénesis.
MX386294B (es) Esteres de oxaborol y sus usos
MX392574B (es) Análogos de compstatina de acción prolongada para usarse en el tratamiento de trastornos oculares
CL2020002561A1 (es) Composiciones y métodos para el tratamiento de la distrofia macular
CU20170038A7 (es) Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
EA201792640A1 (ru) Устойчивые к действию протеазы липидированные аналоги glp-1
MX2019002248A (es) Proteina de union al factor h modificada.